Premium
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine
Author(s) -
Dillon William C.,
Eckert George J.,
Dillon James C.,
Ritchie Michael E.
Publication year - 2000
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/1522-726x(200008)50:4<426::aid-ccd12>3.0.co;2-l
Subject(s) - abciximab , ticlopidine , medicine , clopidogrel , coronary stent , incidence (geometry) , cardiology , platelet , bolus (digestion) , anesthesia , surgery , stent , percutaneous coronary intervention , myocardial infarction , restenosis , physics , optics
The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed. We evaluated the rate of thrombocytopenia in patients undergoing intracoronary stent implantation receiving bolus plus infusion of abciximab and either ticlopidine or clopidogrel. We noted an incidence of 24% with the combination of 300‐mg clopidogrel and abciximab. Other doses of ticlopidine (250 and 500 mg) and clopidogrel (75 mg) did not result in a statistically significant increase in thrombocytopenia over that of the 2.5%–5.2% reported incidence with abciximab alone. Length of hospital stay was 2.3 vs. 6.4 days in those developing thrombocytopenia ( P = 0.06). Four (25%) developed thrombocytopenia requiring blood transfusion. Eight (50%) had no sequelae. The combination of 300‐mg clopidogrel and abciximab results in a significant increase in the incidence of thrombocytopenia. This is an important clinical observation that merits further study. Cathet. Cardiovasc. Intervent. 50:426–430, 2000. © 2000 Wiley‐Liss, Inc.